Know Cancer

or
forgot password

Patient Registry: VIDAZA® in Patients With MDS, CMML or AML


N/A
18 Years
N/A
Open (Enrolling)
Both
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia

Thank you

Trial Information

Patient Registry: VIDAZA® in Patients With MDS, CMML or AML


Inclusion Criteria:



- Patients with MDS, CMML, and AML

- Who begin with or already have received treatment with VIDAZA®

- Who are willing to provide informed consent

Exclusion Criteria:

- Due to the non-interventional design of this program there are no specific exclusion
criteria.

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Response evaluation

Outcome Description:

hematological response, marrow response, cytogenetic response (if data is available), quantification of reduced need for transfusions, median response duration

Safety Issue:

No

Principal Investigator

Richard Greil, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Universitätsklinik für Innere Medizin III der PMU Salzburg

Authority:

Austria: Ethikkommission

Study ID:

AGMT_Vidaza Register

NCT ID:

NCT01595295

Start Date:

February 2009

Completion Date:

Related Keywords:

  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • CMML
  • MDS
  • AML
  • registry
  • Vidaza
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Myelomonocytic, Chronic
  • Myelodysplastic Syndromes
  • Preleukemia
  • Leukemia, Myelomonocytic, Acute

Name

Location